PTK2

Across TCGA pan-cancer cohorts, PTK2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PTK2 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PTK2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PTK2 expression acts as an unfavorable survival marker, although some lineages such as COAD and CCRCC show a favorable association.

HNSC, COAD, and LSCC are the cancer types where PTK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.166	0.964	.024	23	view →
COAD	DFS	Median	II,III,IV	1.000	0.887	.030	18	view →
LSCC	OS	Tertile	III,IV	0.263	0.839	.007	17	view →
PDAC	DFS	Median	All	0.338	0.548	.008	12	view →
CCRCC	DFS	Tertile	III,IV	0.872	0.570	.015	10	view →
LUAD	OS	Median	III,IV	0.670	0.226	.010	7	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PTK2–HNSC (OS)

Open the HNSC breakdown →